## What is claimed is:

1. A compound of formula I, pharmaceutically acceptable salts thereof, or mixtures thereof:

5

15

wherein

 $R^1$  is an aryl, heteroaryl, substituted aryl or substituted heteroaryl; and  $R^2$  is hydrogen, optionally substituted  $C_{1-12}$ alkyl, optionally substituted  $C_{6-12}$ aryl, or optionally substituted  $C_{2-12}$ heterocyclyl.

2. A compound according to claim 1,

wherein R<sup>1</sup> is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; and N-oxido-pyridyl, optionally substituted with one or

more groups selected from C<sub>1-6</sub>alkyl, halogenated C<sub>1-6</sub>alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>, C<sub>1-6</sub> alkoxy, chloro, fluoro, bromo, and iodo; and

R<sup>2</sup> is hydrogen or methyl.

20 3. A compound according to claim 1,

wherein  $R^1$  is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl; and thiazolyl, optionally substituted with one or more groups selected from  $C_{1-6}$ alkyl, halogenated  $C_{1-6}$ alkyl, -NO<sub>2</sub>, -CF<sub>3</sub>,  $C_{1-6}$  alkoxy, chloro, fluoro, bromo, and iodo; and

 $R^2$  is hydrogen or methyl.

WO 2004/041800 PCT/SE2003/001703

37

4. A compound according to claim 1, wherein R<sup>1</sup> is selected from phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl; and thiazolyl; and R<sup>2</sup> is hydrogen or methyl.

5

20

30

- 5. A compound according to claim 1, wherein the compound is selected from:
- 3-[(4-[(diethylamino)carbonyl]phenyl)(4-benzyl-piperazin-1-10 yl)methyl]benzamide;
  - 3-{(4-[(diethylamino)carbonyl]phenyl)[4-(2-furylmethyl)-piperazin-1yl]methyl}benzamide;
- 15 3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]-N-methyl-benzamide; enantiomers thereof; and pharmaceutically acceptable salts thereof.
  - 6. A compound according to any one of claims 1-5 for use as a medicament.
  - 7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain, or functional gastrointestinal disorders.
- 8. A pharmaceutical composition comprising a compound according to any one 25 of claims 1-5 and a pharmaceutically acceptable carrier.
  - 9. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.
  - 10. A method for the therapy of functional gastrointestinal disorders in a warmblooded animal, comprising the step of administering to said animal in need of such

5

therapy a therapeutically effective amount of a compound according to any one of claims 1-5.

11. A process for preparing a compound of formula II,

П

comprising of the step of reacting a compound of formula III:

П

with R<sup>1</sup>-CHO to form the compound of formula II wherein

R<sup>1</sup> is an aryl, heteroaryl, substituted aryl or substituted heteroaryl.

12. A process for preparing a compound of formula IV,

WO 2004/041800 PCT/SE2003/001703

$$\frac{39}{N}$$

comprising: reacting a compound of formula II,

with an akali metal hydroxide in non-aqueous solvent to form the compound of formula IV:

wherein

5

10 R<sup>1</sup> is an aryl, heteroaryl, substituted aryl or substituted heteroaryl.